ObsEva

84 articles with ObsEva

• ObsEva Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule

  9/6/2017

• ObsEva Reports Second Quarter 2017 Financial Results And Provides Business Update

  8/16/2017

• ObsEva To Hold Second Quarter 2017 Financial Results/Business Update Call On August 15, 2017 And Present At Wedbush Pacgrow Healthcare Conference In NYC On August 16, 2017

  8/7/2017

• ObsEva Announces Presentations Related To Its Assisted Reproductive Technology (ART) And Pre-Term Labor (PTL) Development Programs At ESHRE 2017 Annual Meeting

  6/29/2017

• ObsEva Announces The Completion Of A Phase I PK/PD Clinical Trial Evaluating Different Doses Of OBE2109 And Add-Back Therapy

  6/7/2017

• ObsEva Reports First Quarter 2017 Financial Results and Business Update

  5/18/2017

• ObsEva Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022

  5/18/2017

• ObsEva To Hold First Quarter 2017 Financial Results And Business Update Call On Thursday, May 18, 2017

  5/11/2017

• ObsEva Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids

  4/25/2017

• ObsEva To Present Pharmacology Results Demonstrating OBE022 Exerts A Synergistic Effect In Combination With Standard Of Care In Animal Model For Preterm Labor

  3/17/2017

• ObsEva Starts Phase III Clinical Program For Nolasiban In ART

  3/7/2017

• Women's Health Biotech ObsEva to Open Up U.S. HQ in Boston After $97 Million IPO

  1/30/2017

• ObsEva Release: Pharma To Ring The Nasdaq Stock Market Opening Bell In Celebration Of Its IPO

  1/26/2017

• ObsEva Release: Pharma Announces Pricing Of Initial Public Offering

  1/26/2017

• ObsEva Release: Company Expands Leadership Team And Board Of Directors With Industry Veterans

  1/17/2017

• ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor

  1/13/2017

• ObsEva Announces Plans To Conduct Initial Public Offering In The United States

  10/17/2016

• ObsEva To Webcast Presentation At 15th Annual Needham Healthcare Conference

  4/5/2016

• ObsEva Strengthens Board With Appointment Of Biotechnology Veteran Dr. Frank Verwiel

  3/24/2016

• ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis

  11/20/2015